Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1931-1937

  Hymes, Jeffrey ^a   Bickimer, Tammy ^a   Jackson, James H ^b,d   Bookhart, Brahim K ^c   Mody, Samir H ^c   Piech, Catherine Tak ^c  

^a Nephrology Associates   (United States)

^b XCENDA   (United States)

^c Ortho Biotech Products LP   (United States)

^d NONE   (United States)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; Epoetin alfa; Erythropoietic stimulating agents; Medical chart review; Retrospective study; Switching

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; BLOOD ANALYSIS; CHI SQUARE TEST; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DIALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REVIEW; STUDENT T TEST; UNITED STATES;

AGED; AGED, 80 AND OVER; ANEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34548118262     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210705     Document Type: Review

References (36)

1. US Renal Data System. USRDS 2000 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
3. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
4. Abu-Alfa AK. CKD Series. Evaluation and treatment of anemia in chronic kidney disease. Hospital Physician 2003;46:31-8
5. Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12
6. Hsu CY, Bates DW, Kuperman GJ, et al. Relationship between hematocrit and renal function in men and women. Kidney Int 2001;59:725-31
7. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34
8. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8
9. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S1-S146
10. Massimetti C, Pontillo D, Feriozzi S, et al. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 1998;16:317-24
11. Silberberg J, Racine N, Barre P, et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990;6:1-4
12. Zehnder C, Zuber M, Sulzer M, et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992;61:21-5
13. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995;25:548-54
14. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989;110:108-14
15. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and renal function in predialytic uremic patients. Nephron 1992;60:390-6
16. Holland D, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplant 2000;15:650-8
17. Ortho Biotech Products, L.P. Procrit® (epoetin alfa) full prescribing information. Available at http://www.procritline.com/common/ prescribing_information/PROCRIT/PDF/ProcritBooklet.pdf [accessed June 29, 2007]
18. Amgen Inc. Aranesp® (darbepoetin alfa) for injection. Available at http://www.aranesp.com/pdf/aranesp_PI.pdf [accessed June 29, 2007]
19. Singh AK, Szczech L, Tang K, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 2006;355:2085-98
20. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006;355:2071-84
21. Cotter D, Thamer M, Narasimhan, et al. Translating epoetin research into practice: the role of government and the use of scientific evidence. Health Aff (Millwood). 2006;25:1249-59
22. Suranyi MG, Lindberg JS, Navaroo J, et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003;23:106-11
23. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24:453-60
24. Ling B, Walczyk M, Agarwal A, et al. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327-34
25. Papatheofanis F, McKenzie RS, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837-42
26. th Annual Renal Week Meeting of the American Society of Nephrology (ASN)]; 2005 November 8-13; Philadelphia, PA
27. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381-95
28. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47
29. Medi-Span Master Drug Database. Available at: http://www.medispan.com/ Products/index.aspx?id=1 [accessed October 24, 2006]
30. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(Suppl 3):3-13
31. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-5
32. Mody S, Padmanabhan V, McKenzie RS, et al. Epoetin alfa and darbepoetin alfa dosing patterns in pre-dialysis chronic kidney disease patients. Value Health 2006;9:A96 [abstract PUK5]
33. Anon. 2003 Medicare hospital outpatient prospective payment system final rule. Federal Register 2002;67:66757-9
34. Federal Register: June 25, 2004. Department of Health and Human Services Centers for Medicare & Medicaid Services [CMS-9022-N]. From the Federal Register found on www.cms.gov (epoetin alfa search) [from November 15, 2004]: http://www.cms.hhs.gov/providerupdate/regs/cms1427fc_3.pdf
35. Lefebvre P, Mody SH, McKenzie RS, et al. Epoetin alfa and darbepoetin alfa dosing patterns and drug costs in patients with pre-dialysis chronic kidney disease. Am J Kid Dis 2006;47(4):A39 [abstract 84]. Poster presented at the Spring Clinical Meetings of the National Kidney Foundation (NKF); 2006 April 19-23; Chicago, IL
36. McLaughlin T, Mody SH, McKenzie RS, et al. Dosing patterns and associated costs of erythropoietic agents in a nationwide sample of anemic patients with pre-dialysis chronic kidney disease. J Manag Care Pharm 2006;12(2):182 [poster presented at the 18th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy (AMCP)]; 2006 April 5-8; Seattle, Washington